Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA (NYXH) is a medical technology company that develops and commercializes neuromodulation-based therapies for obstructive sleep apnea (OSA), centered on its Genio hypoglossal neurostimulation system. The Nyxoah news feed on Stock Titan brings together company-issued announcements, regulatory disclosures and market updates that reflect how the business is progressing in its target markets.
Investors following Nyxoah’s news can track updates on U.S. and European commercialization of the Genio system, including surgeon training, account activations and the completion of commercial implants. Company press releases describe milestones such as the commercial launch of Genio in new countries, early U.S. implant activity after FDA approval, and developments in reimbursement coverage with public and private payers.
Nyxoah also regularly reports on its financial position and capital markets activity. News items include quarterly financial and operating results, preliminary revenue updates, private placements, registered direct offerings and convertible bond financings, as well as information on voting rights, share capital and transparency notifications regarding significant shareholdings. These disclosures provide context on how the company funds its commercialization and research plans.
In addition, the news stream features regulatory and legal developments, such as FDA approval of the Genio system for a defined subset of adult OSA patients, CE mark expansions, and intellectual property litigation updates referenced in company filings. By reviewing the NYXH news page, readers can see how Nyxoah communicates progress on clinical, regulatory, commercial and financing fronts over time.
Nyxoah (NASDAQ: NYXH) reported preliminary unaudited results for Q4 and full-year 2025 and gave Q1 2026 revenue guidance. Q4 2025 gross revenue is ~€6.3M and net revenue ~€5.7M, up ~348% versus Q4 2024. FY2025 gross revenue is ~€11.0M and net revenue ~€10.0M, up ~122% versus FY2024. Deferred revenue related to disposable patches is ~€0.6M in Q4 and ~€1.0M for FY2025. As of Dec 31, 2025 the company trained 145 surgeons, activated 57 U.S. accounts, and held ~€47.9M in cash, cash equivalents and financial assets. Nyxoah expects U.S. net revenue Q1 2026 to grow ~25% sequentially and international revenue to follow seasonal patterns. Results are preliminary and subject to revision ahead of the 2025 Form 20-F filing.
Nyxoah (Nasdaq: NYXH) received a transparency notification from BNP Paribas Asset Management on January 8, 2026, reporting that BNP Paribas Asset Management Europe SAS holds 1,409,791 voting rights, representing 3.28% of total voting rights as of December 31, 2025 (denominator: 43,026,460).
The crossing of the 3% threshold follows a merger on December 31, 2025 between BNP Paribas Asset Management Europe SAS and AXA Investment Managers SA; the parent holding chain includes BNP Paribas Asset Management Holding and BNP Paribas SA, with an exemption noted under the Royal Decree on disclosure of major shareholdings.
Nyxoah (NASDAQ: NYXH) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 15, 2026. The presentation begins at 12:00 PM PT. A live audio webcast will be available on the company's investor relations website at investors.nyxoah.com.
This presentation offers investors a chance to hear management's update on Nyxoah's neuromodulation therapy for obstructive sleep apnea and company strategy directly from executives.
Nyxoah (NASDAQ/Euronext: NYXH) issued the first tranche of convertible bonds on December 18, 2025, raising €22.5 million of a possible €45 million facility with Heights Capital Management.
The bonds carry a 6.5% annual interest rate, three-year maturity, quarterly amortisation starting Feb 18, 2026, and an initial conversion price of €5.00. An 8% subscription fee (€1.8M) was set off against the proceeds. Proceeds support US commercialization, clinical programs, R&D and general corporate purposes.
Second tranche conditions were not met as of Dec 16, 2025; the first tranche extends cash runway into Q3 2026.
Nyxoah (Nasdaq: NYXH) announced the commercial launch of its Genio bilateral neurostimulation system in the Netherlands on December 17, 2025.
First successful Genio implants were performed at OLVG West (Amsterdam) and Zuyderland Hospital (Heerlen). Management said the system offers bilateral nerve stimulation, no implanted battery, full-body 1.5T and 3T MRI compatibility, and an externally powered activation chip that enables upgrades. Nyxoah described the launch as a step in its European rollout and said early implants validate Genio as a long-term CPAP alternative for patients who cannot tolerate CPAP.
Nyxoah (NASDAQ/Euronext: NYXH) received two transparency notifications from Robert Taub and related BMI Estate disclosing changes in voting rights on November 27 and December 2, 2025.
As of November 20, 2025 the holding totaled 4,290,800 voting rights (9.97%). As of December 1, 2025 the holding rose to 4,360,800 voting rights (10.14%), consisting of 4,310,800 linked securities and 50,000 warrants. The notifications identify controlled undertakings including Robelga SRL and describe ownership chains.
Nyxoah (Nasdaq: NYXH) announced its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec 4, 2025.
The session is scheduled for 1:30 p.m. ET and will be available via a live audio webcast on the company investor relations site at investors.nyxoah.com. The presentation will cover recent corporate developments and provide management commentary to investors and analysts.
Nyxoah (Euronext Brussels & Nasdaq: NYXH) published its updated capital and voting-rights figures on November 20, 2025. Key figures: share capital €6,504,688.76; total securities carrying voting rights 43,026,460 (all ordinary shares); total voting rights (denominator) 43,026,460. The company also reported 3,258,819 rights to subscribe to voting securities not yet issued (these are granted subscription rights) and excluded 692,677 subscription rights that were issued but not yet granted.
This disclosure is provided in accordance with applicable large-shareholding disclosure rules.
Nyxoah (Nasdaq: NYXH) announced financing commitments totaling up to U.S. $77 million to accelerate U.S. commercialization of the Genio system. The package includes a €22 million private placement (5,481,678 shares at €4.00), a U.S. $5.6 million registered direct offering (1,215,964 shares at $4.6304), and a convertible bond facility of up to €45 million (first tranche €22.5 million).
Closings are expected around Nov 17–18, 2025 for equity and Dec 2025 for the first bond tranche. Net proceeds will fund U.S. commercialization, clinical research, R&D, manufacturability and general corporate purposes.
Nyxoah (NASDAQ: NYXH) reported Q3 2025 results on November 13, 2025, following FDA approval and U.S. commercial launch of the Genio system.
Key points: Q3 revenue €2.0M (+56% YoY), first U.S. commercial implants and initial U.S. revenue in September, gross margin 60.5%, cash and financial assets €22.5M on Sept 30, 2025 (down from €43.0M on June 30, 2025), and an operating loss €24.4M for the quarter. The company trained 111 surgeons and reported early reimbursement wins including Medicare and major private payers.
FAQ
What is the current stock price of NYXOAH S A (NYXH)?
What is the market cap of NYXOAH S A (NYXH)?
